|Bid||24.88 x 1100|
|Ask||26.64 x 1100|
|Day's Range||24.81 - 25.42|
|52 Week Range||24.81 - 51.70|
|Beta (3Y Monthly)||1.20|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 24, 2019 - Jul 29, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||33.67|
DUBLIN , May 14, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Senior Vice President of Corporate Planning, Blair Jackson , will participate in a fireside chat at the UBS Global ...
-- Clinical Data and Health Economics and Outcomes Research to be Presented May 18-22, 2019 at APA and ISPOR Annual Meetings -- DUBLIN , May 13, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today ...
Alkermes Plc NASDAQ/NGS:ALKSView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for ALKS with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $4.48 billion over the last one-month into ETFs that hold ALKS are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Here's a roundup of top developments in the biotech space over the last 24 hours. None of the biotech stocks hit 52-week highs Wednesday. Down In The Dumps (Biotech stocks hitting 52-week lows on April ...
-- First Quarter Revenues of $223.1 Million , Primarily Driven by ~8% Year-Over-Year Growth of Proprietary Product Net Sales -- -- Company Reports GAAP Net Loss per Share of $0.62 and Non-GAAP Net Loss ...
NEW YORK, NY / ACCESSWIRE / April 25, 2019 / Alkermes Plc (NASDAQ: ALKS ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on April 25, 2019 at 8:30 AM Eastern ...
DUBLIN, April 24, 2019 /PRNewswire/ -- Alkermes plc (ALKS) today announced that C. Todd Nichols, an executive with more than two decades of extensive commercial experience in the biopharmaceutical sector, will become the company's Senior Vice President of Sales and Marketing effective May 13, 2019. He will serve on the Alkermes executive management team and report to Richard Pops, the company's Chief Executive Officer. Mr. Nichols most recently held the position of Vice President, Marketing and Sales, Inflammation and Immunology at Celgene, where he was responsible for developing and managing all aspects of U.S. commercial planning, brand P&L, strategy development, go-to-market modeling and launch execution for ozanimod. "I am excited to join a company with strong leadership, dedicated employees and that is rooted in its mission to make a positive impact on patients struggling with central nervous system (CNS) disorders," said Mr. Nichols.
Does Alkermes Plc (NASDAQ:ALKS) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on satellite photos and other research activities, so it is no wonder why they tend to […]
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Alkermes plc (NASDAQ:ALKS), with a market cap of US$5.3b, are often out of the spotlight. While they are less talked about as an i...
DUBLIN , April 18, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:30 a.m. ET ( 1:30 p.m. BST ) on Thursday, Apr. 25, 2019 , to discuss the company's ...
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 10) Fulgent Genetics Inc (NASDAQ: FLGT ) Intuitive Surgical, ...
Alkermes (ALKS) reports positive top-line data from phase IIIb study evaluating Aristada and Invega Sustenna in patients with acute exacerbations of schizophrenia.
Alkermes Plc said on Tuesday its long-acting injectable therapy for schizophrenia has helped reduce symptoms and can become an effective option for ensuring patients stay on medication even after being discharged from hospital. The six-month study showed that Alkermes' Aristada, given every two months, was as effective as Johnson & Johnson's monthly injectable Invega Sustenna, with both helping to achieve statistically significant improvements in schizophrenia symptoms. In comparison to long-acting therapies (LATs), commonly prescribed oral antipsychotics are to be taken daily and a brief disruption in treatment can worsen symptoms.
-- Large, randomized ALPINE trial showed both long-acting injectable medications effectively controlled schizophrenia symptoms throughout six-month study -- -- ARISTADA demonstrated significant and similar ...